Cellceutix' (CTIX CEO Leo Ehrlich recently railed against Mako Research for negative articles written about his company. TheStreet's Adam Feuerstein says the rant may have been a smokescreen to divert attention from the company's actual problems. Feuerstein believes the data the company reported concerning the Phase 2 study of its Prurisol drug were exaggerated and the company withheld important negative data from investors.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Video
How Members of Jim Cramer's Action Alerts PLUS Club Made 12% on Kohl's
Jim recommended you buy the stock Monday at about $67 a share.
Striking Options: Crude Surges and Earnings in Full Swing
Global oil prices and geopolitical tensions rise as waivers to buy Iranian oil expire.